Proteomics analysis and evaluation of biomarkers for detection of cholangiocarcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 6, 2011, Pages 1503-1510

  Sriwanitchrak, Pramote ^a,c   Viyanant, Vithoon ^a,c   Chaijaroenkul, Wanna ^a,c   Srivatanakul, Petcharin ^b,c   Gram, Hans Rudi ^a,c   Eursiddhichai, Veerachai ^a,c   Na Bangchang, Kesara ^a,c  

^a THAMMASAT UNIVERSITY   (Thailand)

^b MINISTRY OF PUBLIC HEALTH   (Thailand)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Biomarker; Cancer; Cholangiocarcinoma; Diagnosis; Opisthorchis viverrini

Indexed keywords

EID: 84855415036     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Bamrungphon W, Prempracha N, Bunchu N, et al (2007). A new mucin antibody/enzyme-linked lectin-sandwich assay of serum MUC5AC mucin for the diagnosis of cholangiocarcinoma. Cancer Lett, 247, 301-8.
2. Boonla C, Sripa B, Thuwajit P, et al (2005). MUC1 and MUC5AC mucin expression in liver fluke-associated intrahepatic cholangiocarcinoma. World J Gastroenterol, 11, 4939-46.
3. Carrell RW (1986). Alpha 1-Antitrypsin: molecular pathology, leukocytes, and tissue damage. J Clin Invest, 78, 1427-31.
4. Chaijaroenkul W, Viyanant V, Mahavorasirikul W, Na-Bangchang K (2011). Cytotoxic activities of artemisinin derivatives against cholangiocarcinoma cell line (CL6). Asian Pac J Cancer Prevent, 12, 1-6??.
5. Chalasani N, Baluyut A, Ismail A, et al (2000). Cholangiocarcinoma in patients with primary sclerosing cholangitis: a multicenter case-control study. Hepatology, 31, 7-11.
6. Changbumrung S, Migasena P, Supawan V et al (1988). Serum protease inhibitors in opisthorchiasis, hepatoma, cholangiocarcinoma, and other liver diseases. Southeast Asian J Trop Med Pub Hlth, 19, 299-305.
7. Chidwick K, Whichelow CE, Zhang Z, et al (1994). Relationship between alpha 1-antitrypsin inactivation and tumor necrosis factor alpha concentration in the synovial fluid of patients with rheumatoid arthritis. Arthritis Rheum, 37, 1723-6.
8. Chignard M, Hazouard E, Renesto P, et al (1994). Plasma antiproteinase screen and neutrophil-mediated platelet activation. A major role played by alpha 1 antitrypsin. Biochem Biophys Acta, 1224, 433-40
9. Dbouk HA, Tawil A, Nasr F, Kandakarjian L, Abou-Merhi R (2007). Significance of CEA and VEGF as diagnostic markers of colorectal cancer in Lebanese patients. Open Clin Cancer J, 8, 1-5.
10. Jinawath N, Chamgramol Y, Furukawa Y, et al (2006). Comparison of gene expression profiles between Opisthorchis viverrini and non-Opisthorchis viverrini associated human intrahepatic cholangiocarcinoma. Hepatology, 44, 1025-38.
11. Gatto M, Bragazzi MC, Semeraro R, et al (2010). Cholangiocarcinoma: update and future perspectives. Dig Liver Dis, 42, 253-60.
12. Joo WA, Kang MJ, Son WK, et al (2003). Monitoring protein expression by proteomics: human plasma exposed to benzene. Proteomics, 3, 2402-11.
13. Khan SA, Davidson BR, Goldin R, et al (2002). British Society of Gastroenterology. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut, 51, VI1-9.
14. Khuhaprema T, Srivatanakul P: Liver and Bile Duct. In: Khuhaprema T, Srivatanakul P, H S, Wiangnon S, Sumitsawan Y, Attasara P (eds). Cancer in Thailand, 2007, Vol. IV, 1998-2000. Bangkok Medical Publisher, Bangkok pp. 36-8.
15. Kim MR, Kim CW (2007). Human blood plasma preparation for two-dimensional gel electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci, 849, 203-10.
16. Lempinen M, Isoniemi H, Mäkisalo H, (2007). Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol, 47, 677-83.
17. May WS Jr, Cuatrecasas P (1985). Transferrin receptor: its biological significance. J Membr Biol, 88, 205-15
18. Nehls O, Gregor M, Klump B (2004). Serum and bile markers for cholangiocarcinoma. Semin Liver Dis, 24, 139-54.
19. Park JY, Lee KH (2007). Carcinoembryonic antigen and patterns of recurrence after curative resection of the colorectal cancer. Hepato-gastroenterol, 54, 1966-9
20. Poley JR (1994). Malignant liver disease in alpha 1-antitrypsin deficiency. Acta Paediatr, 393, 27-32
21. Raaf HN, Jacobsen DW, Savon S, Green R (1993). Serum transferrin receptor level is not altered in invasive adenocarcinoma of the breast. Am J Clin Pathol, 99, 232-7
22. Ramage JK, Donaghy A, Farrant JM, Iorns R, Williams R (1995). Serum tumor markers for the diagnosis of cholangiocarcinoma in primary sclerosing cholangitis. Gastroenterol, 108, 865-9.
23. Sajid KM, Parveen R, Durr-e-Sabih, et al. (2007). Carcinoembryonic antigen (CEA) levels in hookah smokers, cigarette smokers and non-smokers. J Pak Med Assoc, 57, 595-9.
24. Shterman N, Kupfer B, Moroz C (1991). Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiol, 59, 19-25
25. Singh NP, Lai H (2001). Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci, 70, 49-56
26. Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al (2004). Proteomic analysis of cholangiocarcinoma cell line. Proteomics, 4, 1135-44.
27. Thongprasert S (2005). The role of chemotherapy in cholangiocarcinoma. Ann Oncol, 16, 93-6
28. Tonouchi A, Ohtsuka M, Ito H et al (2006). Relationship between pancreatic secretory trypsin inhibitor and early recurrence of intrahepatic cholangiocarcinoma following surgical resection. Am J Gastroenterol, 101, 1601-10.
29. Uenishi T, Yamazaki O, Tanaka H, et al (2008). Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol, 5, 583-9.
30. Wang AG, Yoon SY, Oh JH et al (2006). Identification of intrahepatic cholangiocarcinoma related genes by comparison with normal liver tissues using expressed sequence tags. Biochem Biophys Res Commun, 345, 1022-32.